Virbac SA
V16
Company Profile
Business description
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
Contact
13e rue LID - BP 27
Carros06511
FRAT: +33 492087100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
5,620
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,924.20 | 83.70 | 0.95% |
| CAC 40 | 8,052.43 | 58.94 | 0.74% |
| DAX 40 | 23,968.63 | 559.26 | 2.39% |
| Dow JONES (US) | 47,706.51 | 34.29 | -0.07% |
| FTSE 100 | 10,409.53 | 160.01 | 1.56% |
| HKSE | 25,959.90 | 202.61 | 0.79% |
| NASDAQ | 22,697.10 | 1.16 | 0.01% |
| Nikkei 225 | 54,248.39 | 1,372.45 | -2.47% |
| NZX 50 Index | 13,162.79 | 68.42 | 0.52% |
| S&P 500 | 6,781.48 | 14.51 | -0.21% |
| S&P/ASX 200 | 8,692.60 | 90.30 | 1.05% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |